SanBio Company (4592) Q3 2025 earnings summary

Executive summary

• Achieved regulatory approval in Japan for AKUUGO®, a cell therapy for chronic motor paralysis from traumatic brain injury, with shipment delayed to Q2 FY2026 due to manufacturing compliance issues.

• Focus remains on global expansion, especially the US, and new clinical trials for chronic ischemic stroke are planned.

Financial highlights

• Operating loss for the nine months ended October 31, 2024 was ¥2,482 million, an improvement from ¥3,725 million year-over-year.

• Net loss attributable to owners of parent was ¥2,152 million, compared to ¥1,883 million in the prior year.

• Research and development expenses totaled ¥1,666 million, mainly for SB623 program manufacturing.

• Foreign exchange gains of ¥499 million were recorded as non-operating income.

• Comprehensive loss for the period was ¥2,675 million.

Outlook and guidance

• No revision to the full-year forecast; projected net loss for FY2025 is ¥3,359 million, with no dividend planned.

• Earnings forecasts are based on current information and may vary due to various factors.